

# Victor S Lin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8823829/publications.pdf>

Version: 2024-02-01

6  
papers

187  
citations

1684188

5  
h-index

1872680

6  
g-index

6  
all docs

6  
docs citations

6  
times ranked

226  
citing authors

#	ARTICLE	IF	CITATIONS
1	BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. <i>Blood</i> , 2020, 135, 2266-2270.	1.4	67
2	Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. <i>Blood Advances</i> , 2021, 5, 4054-4058.	5.2	39
3	Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. <i>Blood Advances</i> , 2020, 4, 165-173.	5.2	34
4	Clonal hematopoiesis, myeloid disorders and <i>BAX</i> -mutated myelopoiesis in patients receiving venetoclax for CLL. <i>Blood</i> , 2022, 139, 1198-1207.	1.4	34
5	BH3 Mimetics for the Treatment of B-Cell Malignancies—Insights and Lessons from the Clinic. <i>Cancers</i> , 2020, 12, 3353.	3.7	12
6	Venetoclax for the treatment of mantle cell lymphoma. <i>Annals of Lymphoma</i> , 2019, 3, 4-4.	4.5	1